Donepezil for the treatment of agitation in Alzheimer's disease.
BACKGROUND: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. METHODS: We randomly assigned 272 patients with Alzheim...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Massachusetts Medical Society
2007
|
| _version_ | 1826280909852114944 |
|---|---|
| author | Howard, R Juszczak, E Ballard, C Bentham, P Brown, R Bullock, R Burns, A Holmes, C Jacoby, R Johnson, T Knapp, M Lindesay, J O'Brien, J Wilcock, G Katona, C Jones, R DeCesare, J Rodger, M |
| author_facet | Howard, R Juszczak, E Ballard, C Bentham, P Brown, R Bullock, R Burns, A Holmes, C Jacoby, R Johnson, T Knapp, M Lindesay, J O'Brien, J Wilcock, G Katona, C Jones, R DeCesare, J Rodger, M |
| author_sort | Howard, R |
| collection | OXFORD |
| description | BACKGROUND: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. METHODS: We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks. RESULTS: There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval [CI], -4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point; 95% CI, -11.4 to 9.6). There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change. CONCLUSIONS: In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00142324 [ClinicalTrials.gov].). |
| first_indexed | 2024-03-07T00:20:49Z |
| format | Journal article |
| id | oxford-uuid:7c793175-5022-4a6a-be4e-43efe035946e |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:20:49Z |
| publishDate | 2007 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:7c793175-5022-4a6a-be4e-43efe035946e2022-03-26T20:57:24ZDonepezil for the treatment of agitation in Alzheimer's disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7c793175-5022-4a6a-be4e-43efe035946eEnglishSymplectic Elements at OxfordMassachusetts Medical Society2007Howard, RJuszczak, EBallard, CBentham, PBrown, RBullock, RBurns, AHolmes, CJacoby, RJohnson, TKnapp, MLindesay, JO'Brien, JWilcock, GKatona, CJones, RDeCesare, JRodger, MBACKGROUND: Agitation is a common and distressing symptom in patients with Alzheimer's disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear. METHODS: We randomly assigned 272 patients with Alzheimer's disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks. The primary outcome was a change in the score on the Cohen-Mansfield Agitation Inventory (CMAI) (on a scale of 29 to 203, with higher scores indicating more agitation) at 12 weeks. RESULTS: There was no significant difference between the effects of donepezil and those of placebo on the basis of the change in CMAI scores from baseline to 12 weeks (estimated mean difference in change [the value for donepezil minus that for placebo], -0.06; 95% confidence interval [CI], -4.35 to 4.22). Twenty-two of 108 patients (20.4%) in the placebo group and 22 of 113 (19.5%) in the donepezil group had a reduction of 30% or greater in the CMAI score (the value for donepezil minus that for placebo, -0.9 percentage point; 95% CI, -11.4 to 9.6). There were also no significant differences between the placebo and donepezil groups in scores for the Neuropsychiatric Inventory, the Neuropsychiatric Inventory Caregiver Distress Scale, or the Clinician's Global Impression of Change. CONCLUSIONS: In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer's disease. (ClinicalTrials.gov number, NCT00142324 [ClinicalTrials.gov].). |
| spellingShingle | Howard, R Juszczak, E Ballard, C Bentham, P Brown, R Bullock, R Burns, A Holmes, C Jacoby, R Johnson, T Knapp, M Lindesay, J O'Brien, J Wilcock, G Katona, C Jones, R DeCesare, J Rodger, M Donepezil for the treatment of agitation in Alzheimer's disease. |
| title | Donepezil for the treatment of agitation in Alzheimer's disease. |
| title_full | Donepezil for the treatment of agitation in Alzheimer's disease. |
| title_fullStr | Donepezil for the treatment of agitation in Alzheimer's disease. |
| title_full_unstemmed | Donepezil for the treatment of agitation in Alzheimer's disease. |
| title_short | Donepezil for the treatment of agitation in Alzheimer's disease. |
| title_sort | donepezil for the treatment of agitation in alzheimer s disease |
| work_keys_str_mv | AT howardr donepezilforthetreatmentofagitationinalzheimersdisease AT juszczake donepezilforthetreatmentofagitationinalzheimersdisease AT ballardc donepezilforthetreatmentofagitationinalzheimersdisease AT benthamp donepezilforthetreatmentofagitationinalzheimersdisease AT brownr donepezilforthetreatmentofagitationinalzheimersdisease AT bullockr donepezilforthetreatmentofagitationinalzheimersdisease AT burnsa donepezilforthetreatmentofagitationinalzheimersdisease AT holmesc donepezilforthetreatmentofagitationinalzheimersdisease AT jacobyr donepezilforthetreatmentofagitationinalzheimersdisease AT johnsont donepezilforthetreatmentofagitationinalzheimersdisease AT knappm donepezilforthetreatmentofagitationinalzheimersdisease AT lindesayj donepezilforthetreatmentofagitationinalzheimersdisease AT obrienj donepezilforthetreatmentofagitationinalzheimersdisease AT wilcockg donepezilforthetreatmentofagitationinalzheimersdisease AT katonac donepezilforthetreatmentofagitationinalzheimersdisease AT jonesr donepezilforthetreatmentofagitationinalzheimersdisease AT decesarej donepezilforthetreatmentofagitationinalzheimersdisease AT rodgerm donepezilforthetreatmentofagitationinalzheimersdisease |